🔴 Telix Pharmaceuticals is trading 11% down in pre-market after announcing US$1.65 billion acquisition of ITM

Telix Pharmaceuticals is trading 10.96% down now at $11.21 in pre-market after announcing a US$1.65 billion acquisition of ITM Isotope Technologies Munich on September 21, 2026.

• The transaction includes approximately US$1.25 billion in Telix shares, with 105.8 million new shares expected to be issued.
• This creates dilution and gives ITM shareholders roughly 23.7% of the combined company.
• Completion remains subject to shareholder and regulatory approval.